Transvenous removal of pacing and ICD leads: single Italian referral center experience

Introduction

Device related complications are rising the need of Transvenous Lead Removal (TLR). Transvenous extraction of Pacing (PL) and Defibrillating Leads (DL) is a highly effective technique. Aim of this report is to analyse the longstanding experience performed in a single Italian Referral Center.

Methods

From January 1997 to December 2021, we managed 2925 consecutive patients (2220 men, mean age 65.3 years) with 5370 leads (mean dwell time 74.0 months, range 1–576). PL were 4209 (1903 ventricular, 1801 atrial, 505 coronary sinus leads), DL were 1161 (1140 ventricular, 6 atrial, 15 superior vena cava leads). Indications to TLR were infection in 78% (systemic 27%, local 51%) of leads. We performed mechanical dilatation using a single polypropylene sheath technique and, if necessary, other intravascular tools; we performed an approach through the Internal Jugular Vein (JA) in case of free-floating leads or failure of the standard approach.

Results

We attempted removal in 5359 leads because the technique was not applicable in 11 PL. Among these, 5223 leads were completely removed (97.4%), 51 (1.0%) were partially removed, 85 (1.6%) were not removed. Among 5271 exposed leads: manual traction removed 879 (16.7%) leads; mechanical dilatation using the venous entry site removed 3860 (73.2%) leads; femoral approach (FA) removed 50 (0.9%) leads; and JA removed 346 (6.6%) leads. All the free-floating leads were completely removed, 26.1% by FA and 73.9% by JA. Major complications occurred in 23 cases (0.78%): cardiac tamponade (21 cases, 5 deaths), hemothorax (2 cases, 1 death).

Conclusions

Our experience shows that in centers with wide experience, TLR using single sheath mechanical dilatation has a high success rate and a very low incidence of serious complications. TLR through the Internal Jugular Vein increases the effectiveness and safety of the procedure also in case of free-floating or challenging leads.

Funding Acknowledgement

Type of funding sources: None.

ELECTRa Registry Outcome Score (EROS): validation in a single center population

Funding Acknowledgements

Type of funding sources: None.

Introduction

The ELECTRa Registry Outcome Score (EROS) was developed to identify patients at increased transvenous lead extraction (TLE) risk

Purpose

Aim of the study is to explore the efficiency of EROS for stratifying patients undergoing TLE.

Methods

We performed a retrospective analysis of 1293 patients who underwent to TLE in our center. We performed extraction procedures with manual traction or mechanical dilatation. We calculated EROS, and we divided patients into 3 groups depending on the EROS class. For this purpose, we made statistical analysis and comparison between EROS 1+2 vs. EROS 3 groups. We used an X2 for among-group comparisons or Fisher’s exact test if the expected cell count was less than five.

Results

Our analysis included 1293 patients. EROS-1 counted 726 patients (56,1%), EROS-2 367 (28,4%) patients and EROS-3 200 (15,5%) patients. There was no statistical difference in peri-procedural death between EROS-1+2 and EROS-3 (0.18% vs 1.50%, p=0.134). Major complications (0.82% vs. 3.00%, p=0.014), minor complications (3.11% vs. 6.50%, p=0.019) and use of internal jugular approach (6.13% vs. 14.50%, p<0.001) was significantly higher in EROS 3 patients.

Conclusion

EROS effectively separates patients at higher risk of complications. Use of internal jugular approach was significantly higher in EROS 3 patients.

Left atrial thrombus and smoke resolution in patients with atrial fibrillation or flutter under chronic oral anticoagulation

Funding Acknowledgements

Type of funding sources: None.

Introduction

Data on left atrial/left atrial appendage (LA/LAA) thrombus resolution after non–vitamin K antagonist (VKA) oral anticoagulant treatment (OAT) are scarce.

Purpose

The aim of this study was to explore retrospectively the resolution of LA/LAA spontaneous echo-contrast or thrombus in patients with nonvalvular atrial fibrillation (AF) or atrial flutter (AFL) after OAT in a real-world single center practice.

Methods

A single center retrospective analysis of patients with AF/AFL who underwent a transesophageal echocardiography (TEE) for an electrical cardioversion and/or atrial fibrillation ablation was performed. Patients showing LA/LAA echo-contrast or thrombus and with at least one TEE follow up to detect the resolution of LA/LAA echo-contrast/thrombus were included and analyzed.

Results

Among 277 TEE performed, 73 cases (26%) of LA/LAA echo-contrast or thrombus were detected in our hospital. Among them, a total of 53 patients showed LAA/LA echo-contrast (19%) and 20 (7%) patients showed a thrombus. Patients with echo-contrast or thrombus were usually male (78% vs 72%, p=0.05) with more comorbidities, as hypertension (90% vs 72%, p=0.03) and congestive heart failure (36% vs 17%, p=0.007) and with an overall higher CHA2DS2-Vasc score (3.5±1.5 vs 3±1, p=0.0001). All they were under chronic anticoagulation with a VKA (65%) or with a NOAC (35%), without differences between groups. (p=NS). At the TTE/TEE analysis, they showed a comparable ejection fraction (55±11 vs 55±22%, p=NS), a trend for an increased LA dilatation (27±8 vs 26±6 cm2, p=0.07) and a low LAA peak velocity (94% vs 19%, p=0.0001). The Echo-contrast Group maintained the same OAT strategy in 49 patients (93%), switching from VKA to NOAC in 3 cases (6%) and from NOAC to NOAC in 1 (1%). The Thrombus Group kept the same OAT strategy with a NOAC in 6 cases (30%) and changed the strategy in 14 patients (70%). Particularly, they titrated NOAC dose in 1 (5%) and the VKA dose in 4 (20%), switched from NOAC to VKA in 5 (25%), from VKA to NOAC in 3(15%) and from NOAC to NOAC in 1 (5%). Smoke resolution was observed in LA/LAA smoke group in 1/10 cases (10%) after a median time of 52 days (20-135) and LA/LAA thrombus resolution 8/15 (53%) after a median time of 45 days (25-180). Patients with the thrombus resolution had a lower CHA2DS2-Vasc score (3.5±2 vs 4±1, p=0.05), and showed a trend for a more frequent use of a NOAC (37.5 vs 28%, p=0.07) and a longer overall anticoagulation time (7.5 vs 4 months, p=0.08). At one-year follow-up, 1 ischemic stroke (1.9%) and 2 deaths (3.8%) were observed only in the Echo-contrast group.

Conclusion(s)

In OAT patients with an LA/LAA thrombus changing the OAT strategy is associated with thrombus resolution in more than 50% of cases, after an appropriate anticoagulation period and in lower CHAD2S2Vasc patients. Chronic OAT strategy confirmation, also with NOAC, is rarely effective, also in case of echo-contrast resolution.

LSI guided-high power short duration is safe and improves pulmonary vein isolation efficiency

Introduction

High-power short-duration (HPSD) is an increasingly used ablation strategy for pulmonary vein isolation (PVI) procedures, but Lesion Index (LSI)-guided HPSD radio-frequency (RF) application has not been described in this clinical setting.

Purpose

We evaluated the procedural efficiency and safety of an LSI-guided HPSD strategy for atrial fibrillation (AF) ablation.

Methods

Paroxysmal and persistent AF patients scheduled for AF ablation were prospectively enrolled and divided in two groups, according to the ablation power used. The LSI-HP Group included patients ablated with a RF power of 50 Watts and the LSI-LP Group included patients ablated with 35 Watts. All patients underwent only PVI under LSI guidance (LSI between 5.5 and 6 anteriorly; LSI between 4.5 and 5 posteriorly) with a point by point strategy and an inter-lesion distance <6 mm. Procedural efficiency parameters were compared between groups.

Results

Forty-six patients with AF (60% paroxysmal) were prospectively enrolled, 25 in the LSI-HP Group and 21 in the LSI-LP Group. They were usually male (78%) with a low-intermediate CHA2DS2-Vasc score (1.8±1.1), a preserved ejection fraction (60±6%) and moderate left atrial dilatation (45±6 mm). Baseline clinical characteristics resulted comparable between groups (p=NS). PVI was successful in all patients. RF time (30.22±9.04 vs 47.85±11.87 min, p<0.0001), total procedure time (138.7±33.2 vs 177.6±49.77, p=0.006) and fluoroscopy time (13.92±5.34 vs 23.14±10.97 min, p=0.006) were significantly lower in the LSI-HP Group. No complication or steam pops was seen in either group.

Conclusions

LSI-HP AF ablation significantly improves procedural efficiency, reducing ablation time, total procedural duration and fluoroscopy use, while maintaining a comparable safety profile as lower powers.

Funding Acknowledgement

Type of funding sources: None. Figure 1Figure 2

Clinical impact of high density mapping in atypical atrial flutters ablation: outlining critical circuits in complex atrial tachycardias

Introduction

Mapping and ablation of atypical atrial flutter (AFL) continue to be a challenge for clinical electrophysiologists. The advent of high-density (HD) mapping has allowed the generation of electro-anatomic maps with a very high resolution level.

Purpose

In this single center retrospective analysis, we evaluated the clinical impact of the ultra HD activation sequence mapping compared with the standard low density (LD) ablation catheter mapping technique in the treatment of AFLs.

Methods

We performed a 7 years-single center retrospective analysis of patients undergoing radiofrequency ablations (RFA) for right and left atypical AFL. We evaluated procedural and clinical outcomes of patients approached with a Low Density (LD) electro-anatomical (EAM) strategy compared with patients mapped with new automatic multipolar HD Mapping (HD Group).

Results

Seventy-five patients were included. Patients were almost male (60%), relatively old (65±8 years), with a moderate CHA2DS2Vasc score (2.3±1.3), a preserved ejection fraction (58±6) and moderate atrial dilatation (44±7 mm). Baseline clinical characteristics were comparable between groups (p=NS). Among 88 AFLs, 10 (11%) were located in the right and 78 (89%) in the left atrium, including 22 (28%) roof dependent and 37 (47%) mitral dependent (p=NS). Regarding procedural outcomes, Sinus rhythm restoration during ablation was more frequently observed in the HD Group (79% vs 56%, p=0.037), even if no differences in mapping time, procedural time and radiological dose were observed (p=NS). Freedom from AFL/atrial fibrillation (AF) at 1-year was lower in the HD Group (83% vs 45%, p=0.009) with an increased trend for AF recurrences during long term follow-up (17% vs 23% at 1 and 3-years respectively, p=0.059). At the multivariate analysis, HD map (OR 0,17; 95% CI 0,04–0,66) and younger age (OR 1,09; 95% CI 1,01–1,19) were identified as independent predictors of ablation success at 1 year.

Conclusions

Acute procedural success of ablation of atypical atrial flutter is higher in case of HD mapping strategy. Patient age and HD strategy resulted independent predictors of overall atrial arrhythmias recurrences. During follow-up, AFL recurrences are rare beyond 12 months, differently from AF which continues to show increasing trends.

Funding Acknowledgement

Type of funding sources: None. Procedural outcomesAtypical atrial flutter HD map

Off-label combination of leadless pacemakers and subcutaneous defibrillators in bilateral venous occlusion: a new reimplantation strategy after lead extraction

Background

Subcutaneous implantable cardioverter-defibrillator (S-ICD) and leadless pacemakers (LPM) provide an alternative to transvenous implantable devices. Sometimes, after transvenous (TV) lead extraction, patients show a bilateral venous occlusion, resulting not eligible for TV reimplantation.

Purpose

This analysis was designed to provide preliminary data on feasibility and short-term outcome of an hybrid combination (Hyb) of s-ICD plus LPM after TV-ICD explantation, in patients without anatomical transvenous reimplantation options.

Methods

Among 2684 consecutive extracted patients, 31 (1.1%) were reimplanted with a LPM, 66 (2.4%) with a s-ICD and 6 (0.2%) patients with an Hyb combination. Hyb strategy was considered in patients with a pacing plus defibrillating indication, and an anatomical barrier, as bilateral superior venous occlusion or massive bilateral skin erosion.

Results

Hyb patients were old (72±10 years), with a prevalent ischemic disease (4/6) and a reduced ejection fraction (43±16%). Extraction indication was infection in 4 and severe venous occlusion in 2, and included 2 single chamber, 2 dual chamber and 2 biventricular ICD. After extraction, reimplantation timing was 7±6 days, LPM was implanted before and sICD the day after.

LPM reimplantation indication was sinus node dysfunction in 2 and AV block in 4. Implantation duration was 68±23 and fluoroscopy time 9.4±2.3 min. ICD reimplantation indication was primary prevention in 4 and secondary prevention in 2. Implantation duration was 118±10 min. No complications were observed. At 1 year, no complications were observed, including device related cross-talks.

Conclusions

The Hyb strategy is a potential option after TV-ICD explantation in pacemaker dependent patients, when transvenous implantation is not available.

Extraction and Reimplantation Session

Funding Acknowledgement

Type of funding source: None

Real-time local impedance monitoring to assess tissue lesion during pulmonary vein isolation: a new tool for AF ablation

Background

Contact force catheter ablation is the gold standard for treatment of atrial fibrillation (AF). Local tissue impedance (LI) evaluation has been recently studied to evaluate lesion formation during radiofrequency ablation.

Purpose

Aim of the study was to assess the outcomes of an irrigated catether with LI alghorithm compared to contact force (CF)-sensing catheters in the treatment of symptomatic AF.

Methods

A prospective, single-center, nonrandomized study was conducted, to compare outcomes between CF-AF ablation (Group 1) and LI-AF ablation (Group 2). For Group 1 ablation was performed using the Carto 3© System with the SmartTouch SF catheter and, as ablation target, an ablation index value of 500 anterior and 400 posterior. For Group 2, ablation was performed using the Rhythmia™ System with novel ablation catheter with a dedicated algorithm (DirectSense) used to measure LI at the distal electrode of this catheter. An absolute impedance drop greater than 20Ω was used at each targeted. According to the Close Protocol, ablation included a point by point pulmonary vein isolation (PVI) with an Inter-lesion space ≤5 mm in both Groups. Procedural endpoint was PVI, with confirmed bidirectional block.

Results

A total of 116 patients were enrolled, 59 patients in Group 1 (CF) and 57 in Group 2 (LI), 65 (63%) with a paroxismal AF and 36 (37%) with a persistent AF. Baseline patients features were not different between groups (P=ns). LI-Group showed a comparable procedural time (180±89 vs 180±56, P=0.59) but with a longer fluoroscopy time (20±12 vs 13±9 min, P=0.002). Wide antral isolation was more often observed in CF-Group (95% vs 80%, P=0.022), while LI-Group 2 required frequently additional right or left carina ablation (28% vs 14%, P=0.013). The mean LI was 106±14Ω prior to ablation and 92.5±11Ω after ablation (mean LI drop of 13.5±8Ω) during a median RF time of 26 [19–34] sec for each ablation spot. No steam pops or complications during the procedures were reported. The acute procedural success was 100%, with all PVs successfully isolated in all study patients. Regarding safety, only minor vascular complications were observed (5%), without differences between groups (p=0.97). During follow up, 9-month freedom from atrial fibrillation/atrial flutter/atrial tachycardia recurrence was 86% in Group 1 and 75% in Group 2 (P=0.2).

Conclusions

An LI-guided PV ablation strategy seems to be safe and effective, with acute and mid-term outcomes comparable to the current contact force strategy. LI monitoring could be a promising complementary parameter to evaluate not only wall contact but also lesion formation during power delivery.

Procedural Outcomes

Funding Acknowledgement

Type of funding source: None

P1470Outcome of leadless pacemaker implantation in a referral centre for lead extraction: a comparison with transvenous pacemaker

Background

Leadless cardiac pacing is a promising technology in terms of efficacy and safety.

Purpose

The aim of the study was to compare the long-term clinical and electrical performance of Micra leadless pacemaker with ventricular single-chamber transvenous pacemaker (VVI TV-PM) in a high-volume centre for transvenous lead extraction (TLE).

Methods

Between May 2014 and April 2019, 100 patients (group 1) underwent Micra implant at our centre. We identified 100 patients (group 2) who underwent VVI TV-PM implant in the same period for a 1:1 comparison matched by age, sex, left ventricular systolic ejection fraction and  previous TLE.

Results

The implant procedure was successful in all patients. In group 1, the procedure duration was lower than in group 2 (43.86 ± 22.38 vs 58.38 ± 17.85 min, p < 0.001), while the fluoroscopy time was longer (12.25 ± 6.84 vs 5.32 ± 4.42 min, p < 0.001). There was no difference about the rate of septal deployment at the right ventricle (group 1 vs group 2: 76% vs 86%, p = 0.10). Patients were followed-up for a median of 12 months. We did not observe any acute and chronic procedure-related complications in group 1, while we reported acute complications in seven patients (0 vs 7%, p = 0.02) and long-term complications in three patients (0 vs 3%, p = 0.24), needing for a system revisions in 6 cases (0 vs 6%, p = 0.038) in group 2. One systemic infection occurred during follow-up in a patient with VVI TV-PM. Electrical measurements were stable during follow-up in both groups, with a longer estimated battery life in group 1 (mean delivered energy at implant group 1 vs group 2: 0.14 ± 0.21 vs 0.26 ± 0.22 μJ, p < 0.001).

Conclusion

Micra pacemaker implant is a safe and effective procedure, with a lower rate of acute complications and system revisions and a longer estimated battery life compared to VVI TV-PM, even in a real life setting including patients who underwent TLE.

P1469Micra pacemaker implant at septal site induces a smaller increase on qrs duration than traditional pacemaker: a single center experience

BACKGROUND

Leadless pacemakers have been introduced into the clinical practice as a breakthrough technology that could tackle most of the major sources of complication of traditional pacemakers (PM). The excellent safety profile and optimal electrical performance of Micra have been already largely described, nevertheless the impact on QRS duration has not been investigated so far. We aimed to compare changes in QRS duration after septal Micra implant in comparison to patients who received transvenous right ventricular leads in the same position.

METHODS

We enrolled all patients who underwent Micra implantation (group 1) at our Center from April 2017 to March 2019. A septal placement was attempted in all cases. Duration of spontaneous and paced QRS and their difference (delta QRS) were measured using a polygraph. To provide a comparison group, we analyzed the QRS duration in a matched group of patients (group 2) who received a traditional single chamber pacing system with a transvenously implanted lead at septal position in the same period. Confounding variables that were used to provide the control group were age, sex, left ventricle ejection fraction, and rhythm at implant. High pacing threshold was defined as ≥1.0 V at pulse duration of 0.24 ms.

RESULTS

Twenty-eight consecutive patients (mean age 78 ± 3 years; 71.43% males) who underwent successful Micra implant were enrolled. A septal position was achieved in all cases with a single device delivery in 17/28 patients (60.7%). Mean pacing threshold at implant was 0.56 ± 0.34V/0.24 ms with only 3/28 patients (10.7%) presenting a high pacing threshold. No significant differences in demographic, clinical characteristics and ventricular pacing site were observed between groups. QRS duration was slightly longer in group 1 compared to group 2 before implant (median 123 ms (IQR 104-146.5 ms) vs median 116 ms (IQR 90-125 ms); p = 0.09). Nevertheless, there was a significantly lower delta QRS after implant in Micra compared to the traditional pacing group (15.82 ± 31.77 ms vs 35.82 ± 22.13 ms, p = 0.008).

CONCLUSION

Right ventricular stimulation induces ventricular dyssynchrony, which is correlated with the amount of QRS enlargement after pacing. Micra implant, in a non-apical position, produces significantly smaller changes on the QRS duration in comparison with transvenous lead implanted at the same site, although larger studies are necessary to confirm these results.

P2836Role of pre-procedural CT-imaging on catheter ablation in patients with atrial fibrillation: procedural outcomes and radiological exposure

Introduction

Cardiac computerized tomography (CT) is commonly used to study left atrial (LA) and pulmonary veins (PVs) anatomy before atrial fibrillation (AF) ablation. However, it remains unclear whether pre-procedural imaging actually is associated with an improvement of efficiency, efficacy, and safety.

Purpose

Aim of the the study was to determine the impact of pre-procedural imaging using CT with 3-D reconstruction on procedural outcomes and radiological exposure in patients who undergo radiofrequency catheter ablation (RFA) to eliminate AF.

Methods

In this registry, 493 consecutive patients (age 62±8 years, 70% male) with paroxysmal (316) or persistent (177) AF who underwent RFA were included. A CT scan was obtained in 324 (66%) patients (CT Group) prior to RFA, while 169 (34%) didn't have any pre-procedural imaging (No-CT Group). Antral PVs isolation was performed in all patients along using an open-irrigation-tip catheter with a 3-D electroanatomical navigation system. Additional ablation applications were targeted if required. Procedural outcome, including radiological exposure, and clinical outcomes were compared among patients who underwent RFA with (CT-Group) and without (No CT-Group) pre-procedural imaging.

Results

Acute PV isolation was obtained in all patients. Additional ablation targets were targeted along the CTI (71/324 [22%] vs. 40/169 [24%], P=NS), the roof line (74/324 [23%] vs. 40/169 [24%], P=NS), the mitral isthmus (33/324 [10%] vs. 12/169 [7%], P=NS) and CFAEs (28/324 [8.6%] vs. 12/169 [7.1%], P=NS), without significant differences among groups. Complication rate were comparable between CT and No CT patients (4.3% vs 3%, P=0.7). In one Redo procedure of the No-CT Group, for the impossibility of identifying left PVs, a 3D LA fluoro-angiography was performed, which confirmed a left PVs occlusion. (Figure) No differences were observed about mean duration of the procedure (231±60 vs 233±58 min, P=0.7) and fluoroscopy time (13±10 vs 13±8 min, P=0.6) between groups. Cumulative radiation dose resulted significantly higher in the CT-Group (8.9±24 vs 4.8±15 mSV, P=0.02). Compared to paroxistical AF, persistent AF patients showed a comparable procedural-ED (6.6±26 vs 6±19, P=0.8) but with an higher CT-ED (1.7±2.9 vs 1.1±1.9, P=0.01).At 1 year, 227/324 (70%) and 119/169 (70%) of the patients who did and did not have pre-procedural imaging were free from AF (P = NS).

Figure 1

Conclusions

Pre-procedural CT does not improve safety and efficacy of AF ablation, increasing significantly the cumulative radiological exposure. Considering that patients candidate to AF ablation are often young, the cumulative radiation dose per life span and radiation dose reduction strategies should remain a matter of concern for doctors.

Acknowledgement/Funding

None